Eli Lilly (LLY) Could Be 14% Below Fair Value On Fresh Research And Omvoh Data

Eli Lilly (LLY) just inked a research deal with Metis TechBio focused on lipid nanoparticle delivery and followed it with fresh Omvoh data in pediatric ulcerative colitis, giving investors new science-driven talking points.

Against that backdrop, Eli Lilly’s share price has climbed strongly over the past year, with a 1-year share price return supported by a 57.4% 1-year total shareholder return. The 17.62% year-to-date share price return suggests momentum has been building rather than fading.

Scan Eli Lilly’s momentum against a curated group of healthcare peers by checking which tickers are showing similar strength in the 37 healthcare AI stocks.

Bulls point to Eli Lilly’s cardiometabolic engine and fresh Omvoh data. Bears focus on a premium multiple and crowded expectations. The recent surge raises a simple test: Do the current numbers still justify this price?

Most Popular Narrative: 14% Undervalued

Eli Lilly last closed at $1,270.75, while the most followed narrative pegs fair value at $1,477.03, so the story assumes more upside than the current quote reflects.

You are buying a business already growing at 25% annually, with its most important new drug not yet approved and not yet reflected in any revenue number, at a price that a conservative model says is 27 to 32% below fair value. The pricing headwinds are real, but they are happening to a company with manufacturing scale, regulatory depth, and a next-generation compound that has already beaten the highest analyst expectations in Phase 3.

See why 77 investors see Eli Lilly as 14% undervalued.

Result: Fair Value of $1,477.03 (UNDERVALUED)

Still, Eli Lilly’s story can change quickly if pricing pressure on GLP-1 therapies deepens, or if key late-stage trial data undercuts confidence in the pipeline.

Find out about the key risks to this Eli Lilly narrative.

Next Steps

If the mixed mood around Eli Lilly leaves you torn, do not wait for consensus. Weigh the upside against the downside and walk through the 3 key rewards and 1 important warning sign.

Looking for more Eli Lilly style investment ideas?

If Eli Lilly has sharpened your focus on quality, broaden your opportunity set and let the screener surface stocks that match the kind of edge you want.

• Target value first and scan companies that combine quality fundamentals with attractive pricing through the 33 high quality undervalued stocks.
• Prioritise resilience and check out a list of solid balance sheet and fundamentals (25 results) so you can focus on businesses with sturdier financial footing.
• Broaden your watchlist and hunt for 21 high quality undiscovered gems that the crowd may not be paying attention to yet.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com